elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Androgen deprivation therapy
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Androgen deprivation therapy
RIS
0.002
(Research Intensity Score)
Papers
329
Top papers
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
2023 · 586 citations
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
2024 · 277 citations
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
2020 · 1149 citations
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
2019 · 1574 citations
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
2025 · 49 citations
Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments
2023 · 102 citations
Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches
2023 · 134 citations
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
2024 · 60 citations
Modern paradigms for prostate cancer detection and management
2022 · 125 citations
Newest papers
Urethral Metastasis of Therapy‐Induced Neuroendocrine Prostate Cancer Successfully Managed With Chemoradiotherapy: A Case Report
2026
Does the Addition of Androgen Receptor Pathway Inhibitors to Androgen Deprivation Therapy Increase Cardiovascular Events in Advanced Prostate Cancer?
2026
Diagnosis and treatment of metastatic prostate cancer in low- and middle-income countries: challenges, adaptive strategies, and lessons from sub-Saharan Africa
2026
Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer With PSA ‐Discordant Progression: A Case Report
2026
Evolving Systemic Therapy for Prostate Cancer: Pivotal Clinical Trials, Biomarker-Driven Combinations, and Practical Sequencing in the ARSI–PARP–Radioligand Era
2026 · 1 citations
PSMA theranostics in the evolving landscape of metastatic prostate cancer: challenges and opportunities
2026
The efficacy and safety of 177Lu-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC): Single-institution, real-world data.
2026
GMP-compliant automated synthesis and quality control of [177Lu]Lu-PSMA-I&T using the GAIA/LUNA Elysia-Raytest module for the treatment of metastatic castration-resistant prostate cancer
2026
Integrating PSMA Radioligand Therapy with Pelvic Radiotherapy for Men with PSMA detected Oligorecurrent Pelvic Nodal Metastases of Prostate Cancer
2026
Browse all papers →
Androgen deprivation therapy's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Androgen deprivation therapy's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link